Clinical trial
Safety and Efficacy of Talampanel in Glioblastoma Multiforme
NCT00267592 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00267592 |
|---|---|
| Title | Safety and Efficacy of Talampanel in Glioblastoma Multiforme |
| Official title | A Phase II Trial of Talampanel in Conjunction With Radiation Therapy With Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug, Radiation |
| Interventions | Talampanel, Radiation Therapy (RT) 5 days a week +, temozolomide(TMZ) 75mg, adjuvant TMZ 200mg |
| Enrollment | 72 |
| Start date | Dec 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Feb 1, 2011 |
| First posted | Dec 21, 2005 |
| Last update posted | May 19, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: